06.06.2025 • NewsDowMergers & Acquisitions (M&A)

Dow Sells its 50% Ownership in DowAksa

Dow announced that it has signed a sale and purchase agreement to sell its 50% interest in DowAksa to Aksa Akrilik Kimya Sanayii A.Ş., a company of Akkök Holding.

Dow logo outside a building
© JHVEPhoto - stock.adobe.com

Aksa Aksa Akrilik Kimya Sanayii A.Ş., the other 50% joint venture partner, has agreed to acquire Dow's 50% interest. Dow's proceeds from the sale are expected to be $125 million, which reflects, after accounting for debt, an enterprise value of approximately 10x the estimated 2025 operating EBITDA.

Dow's decision to exit the joint venture, which was formed in 2012, is consistent with Dow's best-owner mindset strategy of focusing on its core, high-value downstream businesses. The proceeds from the transaction will be used to support the Company's balanced capital allocation approach.

The sale is expected to close in the third quarter of 2025, subject to customary regulatory approvals and other closing conditions.

BNP Paribas acted as exclusive financial advisor to Dow on this transaction.

Company

Logo:

Dow Chemical Company

2211 HH Dow Way
48674 Midland, MI
US

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read